Stockreport

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent BioPharma, Inc.  (AVBP) 
PDF Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NS [Read more]